- Home
- MBRX
as 01-17-2025 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 5.7M | IPO Year: | 2016 |
| Target Price: | $24.00 | AVG Volume (30 days): | 62.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $6.24 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026
MT Newswires
a month ago
Moleculin Biotech Shares Rise After Announcing Preclinical Data for Annamycin Targeting Venetoclax-Resistant Leukemia
PR Newswire
a month ago
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
PR Newswire
2 months ago
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML
PR Newswire
2 months ago
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
TipRanks
2 months ago
Moleculin Biotech Reports Financial Highlights and Future Plans
PR Newswire
2 months ago
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
Thomson Reuters StreetEvents
2 months ago
Q3 2024 Moleculin Biotech Inc Earnings Call
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.